在B细胞中对伊诺图祖马布臭胺素的反应和耐药性的基因组决定因素ALL
medRxiv : the preprint server for health sciences
|December 18, 2023
概括
在CD22的遗传突变驱动B细胞急性淋巴细胞白血病中对伊诺图祖马布臭加米辛 (InO) 治疗的耐药性. 了解这些CD22逃生机制,包括高突变和DNA损伤反应改变,可以改善未来的治疗方法.
科学领域:
- 在瘤学瘤学.
- 遗传学 遗传学是一种遗传学.
- 免疫治疗是一种免疫疗法.
背景情况:
- 伊诺图祖马布 (Inotuzumab ozogamicin,简称InO) 是一种针对CD22表达B细胞恶性瘤的抗体-药物结合物.
- 了解影响INO反应的基因组因素对于优化治疗策略至关重要.
研究的目的:
- 研究B细胞急性淋巴细胞白血病中对伊诺图祖马布奥佐加米辛的反应和耐药性的基因组决定因素.
- 确定CD22抗原逃逸的机制和DNA损伤反应途径的改变.
主要方法:
- 对一组B细胞急性淋巴细胞白血病患者的回顾性分析,这些患者接受了InO治疗.
- 来自因诺治疗后复发的患者的瘤样本的基因组测序.
主要成果:
- 在11%的复发样本中发现了CD22基因的获得突变,导致蛋白质截断,不稳定和表皮质改变等机制.
- 由于易发生错误的DNA损伤修复途径 (替代末端连接,不匹配修复缺陷) 而导致的超突变是CD22逃逸的关键因素.
- 观察到TP53,ATM和CDKN2A的功能丧失突变,这表明受损的DNA损伤检查点有助于逃避亡.
结论:
- 影响CD22表达和DNA损伤反应的遗传变化显著影响了InO的疗效.
- 确定了CD22逃生策略,为开发改进的治疗方法和克服治疗耐药性提供了洞察力.
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K


